Global Ursodeoxycholic Acid API Market Size By Type (Synthetic UDCA, Extraction UDCA), By Application (Pharmacy, Health Products), By Region, And Segment Forecasts, 2023 to 2032

The Global Ursodeoxycholic Acid (UDCA) API Market was valued at USD X.X billion in 2023 and is projected to reach USD X.X billion by 2031, growing at a CAGR of X.X% during the forecast period from 2023 to 2031.

The market growth is driven by the rising prevalence of liver diseases, increasing demand for gallstone treatment, and expanding pharmaceutical applications of UDCA. Ursodeoxycholic acid API is a key ingredient in the production of bile acid-related drugs, widely used in treating cholestatic liver diseases, primary biliary cholangitis (PBC), and gallstones.

Moreover, the growing adoption of UDCA in the pharmaceutical industry for its hepatoprotective properties and its use in combination therapies for various liver disorders are further fueling market expansion. The rising incidence of non-alcoholic fatty liver disease (NAFLD) and growing research into UDCA’s potential benefits in metabolic disorders are anticipated to create new growth opportunities in the market.

Market Drivers

1. Rising Prevalence of Liver Diseases

Increasing cases of primary biliary cholangitis (PBC), primary sclerosing cholangitis (PSC), and non-alcoholic fatty liver disease (NAFLD) are driving demand for UDCA-based medications.

UDCA is commonly prescribed for cholestatic liver diseases to improve bile flow and reduce liver damage.

2. Growing Demand for Gallstone Treatment

UDCA is widely used as a non-surgical treatment option for gallstones in patients who cannot undergo surgery.

Increasing obesity rates and dietary habits contribute to the rising incidence of gallstones, boosting UDCA demand.

3. Expanding Pharmaceutical Applications

Beyond liver diseases, UDCA is being explored for metabolic disorders, gastrointestinal diseases, and cystic fibrosis.

Ongoing research into its anti-inflammatory and cytoprotective properties is expanding its pharmaceutical applications.

Market Restraints

1. Side Effects and Safety Concerns

Some patients experience gastrointestinal side effects, diarrhea, and drug interactions, which may limit widespread use.

Long-term UDCA therapy requires monitoring for hepatotoxicity in certain cases.

2. Availability of Alternative Therapies

Surgical interventions (cholecystectomy) for gallstones and newer drugs for liver diseases may limit market expansion.

The introduction of synthetic bile acid analogs poses competition to UDCA-based treatments.

3. Stringent Regulatory Approvals

Regulatory challenges for UDCA API manufacturing and compliance with pharmaceutical standards may impact production and pricing.

Approval processes for new formulations and combinations remain time-consuming.

Market Opportunity

1. Emerging Markets and Healthcare Expansion

Growing healthcare infrastructure and increasing access to liver disease treatments in Asia-Pacific, Latin America, and the Middle East present lucrative opportunities.

Rising awareness about bile acid disorders in developing regions will drive demand.

2. Combination Therapies and New Drug Development

UDCA in combination with other hepatoprotective agents is gaining traction, expanding its therapeutic scope.

Increasing R&D investments in bile acid-based drugs will support new product launches.

3. Expansion into Veterinary Medicine

UDCA is also being explored for canine and feline liver diseases, creating additional revenue streams for API manufacturers.

Growing awareness of pet healthcare supports market expansion in the veterinary pharmaceuticals sector.

Market by Application Insights

1. Primary Biliary Cholangitis (PBC)

The largest segment in 2023, as UDCA is the first-line treatment for this chronic liver disease.

Ongoing clinical trials exploring UDCA’s efficacy in progressive liver diseases further support market growth.

2. Gallstone Dissolution

A significant share of the market is attributed to UDCA’s role in non-surgical gallstone management.

Increasing preference for non-invasive treatments fuels demand in this segment.

3. Cystic Fibrosis and Other Liver Disorders

Emerging application areas include cystic fibrosis-related liver diseases, intrahepatic cholestasis of pregnancy (ICP), and metabolic disorders.

Expanding research on UDCA in inflammatory and autoimmune conditions is expected to drive growth.

Market by Regional Insights

1. North America

Largest market share in 2023, driven by high awareness, strong healthcare infrastructure, and increasing liver disease prevalence.

The presence of major pharmaceutical companies and API manufacturers supports market expansion.

2. Europe

Significant market presence due to favorable healthcare policies and extensive research on liver disease treatments.

Countries like Germany, the UK, and France lead in UDCA consumption.

3. Asia-Pacific

Fastest-growing region, with rising liver disease burden, expanding pharmaceutical industry, and increasing healthcare spending.

China and India dominate UDCA API production, making them key players in the global supply chain.

4. Latin America & Middle East

Emerging markets with growing healthcare investments and an increasing focus on treating liver disorders.

Governments and healthcare providers are expanding access to UDCA-based treatments.

Competitive Scenario

Key players operating in the Global Ursodeoxycholic Acid API Market include:

ICE S.p.A.

Dipharma Francis S.r.l.

Daewoong Pharmaceutical Co., Ltd.

Mitsubishi Tanabe Pharma Corporation

Grindeks

Suzhou Tianlu Bio-Pharmaceutical Co., Ltd.

Biotavia Labs Pvt Ltd.

Erregierre S.p.A.

PharmaZell GmbH

Zhejiang Conba Pharmaceutical Co., Ltd.

Key Developments:

2023: Mitsubishi Tanabe Pharma launched new formulations of UDCA with improved bioavailability.

2024: ICE S.p.A. announced an expansion of its UDCA API production facility to meet increasing global demand.

2025: Dipharma Francis S.r.l. entered into a strategic collaboration with a major pharmaceutical firm for UDCA combination therapies.

Scope of Work – Global Ursodeoxycholic Acid API Market